Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.75 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.69 |
| ▸ | PNP | P00491 | 10/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571645 | 0.86 | TK1 (1.00) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL8175624 | 0.85 | TK1 (0.97) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL3836263 | 0.84 | TK1 (0.92) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL8196749 | 0.84 | TK1 (0.78) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL29286376 | 0.84 | TK1 (0.76) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL8522271 | 0.83 | TK1 (0.76) | TK1HPRT1PNP | |
| SCHEMBL15743134 | 0.83 | TK1 (0.76) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL3793003 | 0.83 | TK1 (0.76) | TK1HPRT1PNP | |
| SCHEMBL6272299 | 0.82 | TK1 (0.74) | TK1HPRT1PNP | |
| SCHEMBL22571178 | 0.82 | TK1 (0.74) | TK1HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060228305-A1 | Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-12 | — | — | US | disclosed |
| EP-1592422-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS OF TNF ALPHA SYNTHESIS OR ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004071383-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS OF TNF ALPHA SYNTHESIS OR ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| EP-0767793-B1 | N-SUBSTITUTED-(DIHYDROXYBORYL)ALKYL PURINE, INDOLE AND PYRIMIDINE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | UNIV NORTH CAROLINA (US) | 2002-09-18 | — | — | EP | disclosed |
| US-5643893-A | ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | MACRONEX, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0767793-A1 | N-SUBSTITUTED-(DIHYDROXYBORYL)ALKYL PURINE, INDOLE AND PYRIMIDINE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | MACRONEX, INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1995035300-A1 | N-SUBSTITUTED-(DIHYDROXYBORYL)ALKYL PURINE, INDOLE AND PYRIMIDINE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | MACRONEX, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228305-A1 | Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action | CHRNA1, CHRNG, CHRNB1 | TK1 3404/4885HPRT1 2900/4885PNP 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.